C03870: Identification and treatment of cancers with epigenetic silencing of SOCS/CIS genes.Value Proposition:
• Methods for early detection, progression, and recurrence of hematological malignancies
• Predictive biomarker useful for determining sensitivity to JAK inhibitors
• Methods to aid in risk assessment of primary and secondary hematopoietic malignancies
Technical Details:
Scientists have identified Suppressors Of Cytokine Signaling (SOCS-1) as an epigenetic biomarker and therapeutic target for hematological malignancies and other cancers. SOCS family of proteins has been implicated in the negative regulation of several cytokine pathways, particularly the Jak/STAT pathways. Aberrant SOCS-1 methylation was found in the IL-6-dependent Multiple Myeloma cell lines U266 and XG1, which correlated with transcriptional silencing. Methylation-associated inactivation of SOCS-1 in hematopoietic cell lines correlated with greater sensitivity to the chemical JAK inhibitor AG490. Studies suggest that SOCS-1 is frequently inactivated by hypermethylation in myeloma. Unregulated cell growth in cancer may occur due to epigenetic silencing of a suppressor of cytokine signaling (SOCS)/cytokine-inducible SH2 protein (CIS) family member (SOCS/CIS) gene.
Looking for Partners:
This technology may be developed to identify and treat cancers with methylation-silenced transcription of SOCS/CIS gene.
Publications/Associated Cases:
Galm, O., Yoshikawa, H., Esteller, M., Osieka, R., & Herman, J. G. (2003). SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood, 101(7), 2784-2788.
